KIGALI– The Ministry of Health in Rwanda has officially confirmed cases of Marburg virus disease (MVD), a severe hemorrhagic fever, in several patients being treated at health facilities nationwide.
This announcement was made in a statement released on Friday, September 27. The Ministry stated that investigations are underway to determine the source of the infection.
The Ministry of Health announced that enhanced preventive measures will be implemented to combat the viral disease, which causes a highly virulent hemorrhagic fever with a fatality rate of up to 88 percent.
“Marburg virus disease (MVD), a haemorrhagic fever, has been confirmed in a few patients in health facilities in the country. Investigations are being carried out to determine the origin of the infection. Enhanced preventive measures are being implemented in all health facilities. Contact tracing is underway, and cases have been isolated for treatment.” The ministry announced.
“Such infections are transmitted through contact with blood and body fluids of people who are visibly sick. The virus is not believed to be transmitted by air.” they added.
Citizens are urged to contact the Rwanda Biomedical Centre (RBC) at 114 or visit the nearest health facility if they experience symptoms such as high fever, severe headaches, vomiting, muscle aches, or stomach pains.
However, the public has been encouraged to continue their daily activities while remaining vigilant and practicing good hygiene.
“The Ministry of Health is closely monitoring the situation and will provide further updates on a regular basis. The public should continue with their usual activities while maintaining a high level of vigilance and hygiene.” The ministry said in a statement.
About Marburg Virus Disease
Marburg virus disease, previously known as Marburg hemorrhagic fever, is a viral hemorrhagic fever affecting both humans and non-human primates. It is caused by either of the two Marburg viruses: Marburg virus and Ravn virus.
The early signs of Marburg virus disease begin with a nonspecific prodromal phase, marked by low-grade fever, malaise, and body aches. This phase is followed by the appearance of a maculopapular rash on the upper body around days 3 or 4, which may also extend to the lower body in some patients.
As the illness progresses, patients may experience gastrointestinal symptoms such as nausea and loss of appetite, along with mild upper respiratory issues. In severe cases, the disease can lead to complications like encephalopathy, shock, and bleeding, ultimately resulting in death
